Updating results

889 results for end of life Sort: Relevance | Date

End of life care

All NICE products on End of life care. Includes any guidance, NICE Pathways and quality standards.

End of life care for infants, children and young people with life-limiting conditions: planning and management (NG61)

Evidence-based recommendations on managment of end of life care for infants, children and young people (aged 0–17 years) with life-limiting conditions

NICE guideline Published December 2016

End of life care for people with life-limiting conditions

Everything NICE has said about the care of people with a progressive life-limiting condition who are at the end of their life in an interactive flowchart

NICE Pathway Published March 2017 Last updated September 2017

Sharing end of life decisions: Carrying out mum's wishes

Annabel Dawson, lay reviewer for National Institute for Health Research discussed the importance of end of life planning

News Published January 2019

Care of dying adults in the last days of life (NG31)

Evidence-based recommendations on the clinical care of dying adults at the very end of life

NICE guideline Published December 2015

Palliative care for adults: strong opioids for pain relief (CG140)

Evidence-based recommendations on strong opioids for pain relief for adults having palliative (end of life) care

Clinical guideline Published May 2012 Last updated August 2016

End of life care for adults in the last year of life: service delivery

In development [GID-CGWAVE0799] Expected publication date: TBC

NICE guideline In development

Networked approach to implementing NG61 (End of life care for infants, children & young people)

Shared learning Published January 2018 Last updated February 2018

The diagnosis of levels of distress for end of life residents in care homes

Shared learning Published October 2014 Last updated April 2015

Care and support of people growing older with learning disabilities (NG96)

Evidence-based recommendations on care and support for adults with learning disabilities as they grow older

NICE guideline Published April 2018

Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation (CG135)

Evidence-based recommendations on identifying potential organ donors and obtaining consent for deceased organ donation for transplantation

Clinical guideline Published December 2011 Last updated December 2016

Motor neurone disease: assessment and management (NG42)

Evidence-based recommendations for assessing and managing motor neurone disease (MND), also known as amyotrophic lateral sclerosis (ALS).

NICE guideline Published February 2016

Anticipatory prescribing:- What is the clinical and cost effectiveness of anticipatory prescribing for patients dying in their usual place of residence, on patient and carer reported symptoms at end of life?

their usual place of residence, on patient and carer reported symptoms at end of life? Any explanatory notes(if applicable) Why this is...

Research recommendation Published January 2016

Transition between inpatient hospital settings and community or care home settings for adults with social care needs (NG27)

Evidence-based recommendations on the transition between inpatient hospital settings and community or care homes for adults with social care needs.

NICE guideline Published December 2015

Motor neurone disease

Everything NICE has said on assessing and managing motor neurone disease in adults in an interactive flowchart

NICE Pathway Published November 2013 Last updated October 2018

Endocrine cancers

Everything NICE has said on endocrine cancers in an interactive flowchart

NICE Pathway Published March 2018 Last updated December 2018

Care of dying adults in the last days of life (QS144)

Evidence-based statements to deliver quality improvements in the care of dying adults (aged 18 and over) in the last 2 to 3 days of life

Quality standard Published March 2017

Managing breakthrough pain:- What is the acceptability, safety, and effectiveness of different types of opioid analgesia for breakthrough pain in children and young people with life-limiting conditions who are having end of life care in the community?

breakthrough pain in children and young people with life-limiting conditions who are having end of life care in the...

Research recommendation Published February 2017

Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults

Technology appraisal guidance Published June 2017

Myeloma: diagnosis and management (NG35)

Evidence-based recommendations on the diagnosing and managing of myeloma in people aged 16 and over.

NICE guideline Published February 2016 Last updated October 2018

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

Technology appraisal guidance Published August 2018

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults

Technology appraisal guidance Published January 2017

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

Evidence-based recommendations on ixazomib (Ninlaro) with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Technology appraisal guidance Published February 2018

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults

Technology appraisal guidance Published September 2017

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

People's experience in adult social care services: improving the experience of care and support for people using adult social care services (NG86)

Evidence-based recommendations on the care and support of adults receiving social care in their own homes, residential care and community settings

NICE guideline Published February 2018

Bladder cancer

Everything NICE has said on bladder cancer in adults in an interactive flowchart

NICE Pathway Published December 2015 Last updated September 2018

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults

Technology appraisal guidance Published March 2018

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults

Technology appraisal guidance Published June 2017

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Technology appraisal guidance Published February 2017

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults

Technology appraisal guidance Published April 2018

Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)

Evidence-based recommendations on diagnosing and managing idiopathic pulmonary fibrosis (IPF) (hardening of the lungs) in adults

Clinical guideline Published June 2013 Last updated May 2017

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults

Technology appraisal guidance Published June 2017

Carfilzomib for previously treated multiple myeloma (TA457)

Evidence-based recommendations on carfilzomib (Kyprolis) for treating multiple myeloma in adults

Technology appraisal guidance Published July 2017

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557)

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung

Technology appraisal guidance Published January 2019

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course

Technology appraisal guidance Published March 2018

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published June 2018